If billionaire “prospector” Mark Creasy has the Midas touch when it comes to divining lucrative mineral deposits, Paul Hopper just might be the man who wields the mythical rod of Asclepius - the Greek God of medicine - when it comes to the equally lucrative ASX-listed biotechnology space. By any measure Hopper has experienced success listing and developing biotech companies on the ASX – and the last year was a good one.
